Sitafloxacin Anhydrous

Summary

Sitafloxacin Anhydrous (CHEMBL108821) is a phase-3 clinical-stage small molecule; indicated across 1 condition including tuberculosis.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 1 condition
• Clinical trials: 5
• Chemistry: 409.8 Da · C19H18ClF2N3O3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL108821
Name	Sitafloxacin Anhydrous
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	461399
Molecular formula	C19H18ClF2N3O3
Molecular weight	409.8
InChIKey	PNUZDKCDAWUEGK-CYZMBNFOSA-N

SMILES: C1CC12CN(C[C@H]2N)C3=C(C=C4C(=C3Cl)N(C=C(C4=O)C(=O)O)[C@@H]5C[C@@H]5F)F

IUPAC name: 7-[(7S)-7-amino-5-azaspiro[2.4]heptan-5-yl]-8-chloro-6-fluoro-1-[(1R,2S)-2-fluorocyclopropyl]-4-oxoquinoline-3-carboxylic acid

Also known as: DU-6859, Sitafloxacin anhydrous, Sitafloxacin, sitafloxacin, SITAFLOXACINE, SITAFLOXACIN ANHYDROUS, SITAFLOXACIN HYDRATE, Sitafloxacin hydrate, C0088598

Parent form; salt/anhydrous children: CHEMBL3989504

Patent coverage: 1,169 distinct patent families (4,342 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 4,262 (98%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
tuberculosis	3	MONDO:0018076	MONDO:0018076

Clinical trials

Total trials: 5.

Phase distribution

Phase	Trials
PHASE2	2
PHASE4	1
PHASE2/PHASE3	1
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05400369	PHASE4	COMPLETED	A Study to Evaluate the Efficacy and Safety of Sitafloxacin in Adult Subjects With Acute Exacerbation of Chronic Obstructive Pulmonary Disease
NCT05454345	PHASE3	NOT_YET_RECRUITING	Sitafloxacin-containing Regimens for Shortening Tuberculosis Treatment
NCT02729116	PHASE2/PHASE3	UNKNOWN	Sitafloxacin and Ertapenem Treatment for Acute Urinary Tract Infection Caused by E. Coli or K. Pneumoniae in Post-kidney Transplantation Patients
NCT06809413	PHASE2	ENROLLING_BY_INVITATION	Clinical Study on the Early Bactericidal Activity of Sitafloxacin Against Mycobacterium Abscessus Disease
NCT02537847	PHASE2	UNKNOWN	Sitafloxacin and Ertapenem Treatment for Acute Pyelonephritis Caused by Escherichia Coli

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).